SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bill small who wrote (3981)4/3/1998 1:14:00 PM
From: StockDoc  Read Replies (2) of 6136
 
Hi there, just joining.
The potential market for AG3340, if it works better or safer than its competitor compounds, is gigantic. Far bigger than any AIDS drug or all of them, combined. My estimate is over 10 B/y. The competition is in the metalloproteinase and angiogenesis inhibitor fields. The ideal drug is oral, inexpensive, non-toxic and curative. I think AG3340 is oral and might not be very expensive. However, I'm aware of only one entirely safe and curative drug but it is an injectable (disadvantage) peptide (expensive) combination, still in animal models.
StockDoc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News